Position in TLPH
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$116,699
-$61,617 QoQ
Shares Held
113,300
-52.3% QoQ
Ownership
0.218%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#17
of 49 holders
Holding Since
Mar 2023
9 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TLPH Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026RENAISSANCE TECHNOLOGIES LLC holds $2,242,924,243 across 49 Drug Manufacturers - Specialty & Generic names. TLPH ranks #44 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
1,708,739 | $925,846,052 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
2,335,897 | $393,692,080 | |
| 3 | ALKS |
Alkermes plc.
|
6,460,928 | $338,552,627 | |
| 4 | RDY |
Dr Reddys Laboratories Ltd
|
7,347,028 | $106,458,435 | |
| 5 | ZTS |
Zoetis Inc.
|
1,403,300 | $100,841,138 | |
| 6 | SUPN |
Supernus Pharmaceuticals, Inc.
|
1,478,180 | $68,750,151 | |
| 7 | COLL |
Collegium Pharmaceutical, Inc
|
1,366,549 | $49,469,073 | |
| 8 | PCRX |
Pacira BioSciences, Inc.
|
1,733,801 | $43,986,531 |
All Filings in TLPH
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $116,699 | 113,300 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $178,316 | 237,755 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $293,413 | 257,380 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $44,690 | 50,214 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $10,361 | 22,526 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $6,050 | 12,100 | Shares | Sole | 2025-05-14 | |
| 2024-12-31 | $10,214 | 19,643 | Shares | Sole | 2025-02-13 | |
| 2024-03-31 | $22,216 | 21,569 | Shares | Sole | 2024-05-13 | |
| 2023-03-31 | $26,718 | 40,482 | Shares | Sole | 2023-05-12 | |
| No filing history on record for this holder in this stock. | ||||||